Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Tüyap highlights MENA sourcing opportunities at the carpet expo in Istanbul

    November 17, 2026

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    Facebook X (Twitter) Instagram
    Tanta TimesTanta Times
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tanta TimesTanta Times
    Home » Korea to receive 40 million COVID vaccines from Moderna
    Health

    Korea to receive 40 million COVID vaccines from Moderna

    March 4, 2021
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Moderna Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, confirmed that the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government’s aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, deliveries would begin in May 2021.

    Korea to receive 40 million COVID vaccines from Moderna
    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. 

    The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

    Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit their website.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026
    Editor's Pick

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    Morocco secures €434.4 million AfDB loan for reforms

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026
    © 2026 Tanta Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.